Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes

Experimental Eye Research

Volumn 89, Issue 1, 2009, Pages 71-78

  Li, Jingming ^a,b   Wang, Joshua J ^b   Chen, Danyang ^b   Mott, Robert ^b   Yu, Qiang ^a   Ma, Jian xing ^b   Zhang, Sarah X ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

blood retina barrier; diabetic retinopathy; inflammation; statin; tight junction

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; MEVINOLIN; OCCLUDIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR ENDOTHELIAL CADHERIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD RETINA BARRIER; BLOOD VESSEL PERMEABILITY; CELL JUNCTION; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFECT; ENDOTHELIUM CELL; MALE; MOUSE; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA BLOOD VESSEL; RETINA CAPILLARY; RETINA CELL; RETINITIS; TIGHT JUNCTION;

ANIMALS; BLOOD-RETINAL BARRIER; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DRUG EVALUATION, PRECLINICAL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; LIPIDS; LOVASTATIN; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; RETINA; RETINAL PIGMENT EPITHELIUM; TIGHT JUNCTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67349092809     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2009.02.013     Document Type: Article

References (38)

1. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care 30 Suppl. 1 (2007) S4-S41
2. Bamforth S.D., Lightman S., and Greenwood J. The effect of TNF-alpha and IL-6 on the permeability of the rat blood-retinal barrier in vivo. Acta Neuropathol. 91 6 (1996) 624-632
3. Clausen P., Jacobsen P., Rossing K., Jensen J.S., Parving H.H., and Feldt-Rasmussen B. Plasma concentrations of VCAM-1 and ICAM-1 are elevated in patients with type 1 diabetes mellitus with microalbuminuria and overt nephropathy. Diabet. Med. 17 9 (2000) 644-649
4. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., Thomason M.J., Fuller J.H., and CARDS Investigators. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 48 12 (2005) 2482-2485
5. Collins R., Armitage J., Parish S., Sleight P., Peto R., and Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363 9411 (2004) 757-767
6. Cunha-Vaz J. Lowering the risk of visual impairment and blindness. Diabet. Med. 15 Suppl. 4 (1998) S47-50
7. Cusick M., Chew E.Y., Chan C.C., Kruth H.S., Murphy R.P., and Ferris III F.L. Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels. Ophthalmology 110 11 (2003) 2126-2133
8. Danesh F.R., and Kanwar Y.S. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J. 18 7 (2004) 805-815
9. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for DME early treatment diabetic retinopathy study report number 1. Arch. Ophthalmol. 103 (1985) 1796-1806
10. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 98 5 Suppl. (1991) 766-785
11. Fong D.S., Aiello L., Gardner T.W., King G.L., Blankenship G., Cavallerano J.D., Ferris III F.L., Klein R., and American Diabetes Association. Diabetic retinopathy. Diabetes Care 26 1 (2003) 226-229
12. Funatsu H., Yamashita H., Noma H., Mimura T., Yamashita T., and Hori S. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am. J. Ophthalmol. 133 1 (2002) 70-77
13. Funatsu H., Yamashita H., Ikeda T., Mimura T., Eguchi S., and Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 110 9 (2003) 1690-1696
14. Gegg M.E., Harry R., Hankey D., Zambarakji H., Pryce G., Baker D., Adamson P., Calder V., and Greenwood J. Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction. J. Immunol. 174 4 (2005) 2327-2335
15. Girach A., and Lund-Andersen H. Diabetic macular oedema: a clinical overview. Int. J. Clin. Pract. 61 1 (2007) 88-97
16. Gupta A., Gupta V., Thapar S., and Bhansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am. J. Ophthalmol. 137 4 (2004) 675-682
17. Haslinger B., Kleemann R., Toet K.H., and Kooistra T. Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-alpha-activated human peritoneal mesothelial cells. Kidney Int. 63 6 (2003) 2065-2074
18. Joussen A.M., Poulaki V., Mitsiades N., Kirchhof B., Koizumi K., Dohmen S., and Adamis A.P. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 16 3 (2002) 438-440
19. Joussen A.M., Poulaki V., Qin W., Kirchhof B., Mitsiades N., Wiegand S.J., Rudge J., Yancopoulos G.D., and Adamis A.P. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am. J. Pathol. 160 2 (2002) 501-509
20. Kern T.S. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp. Diabetes Res. 2007 (2007) 95103
21. Kim I., Moon S.O., Park S.K., Kwang S., Chae S.W., and Koh G.Y. Angiopoietin-1 Reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and e-selectin expression. Circ. Res. 89 (2001) 477-479
22. Koizumi K., Poulaki V., Doehmen S., Welsandt G., Radetzky S., Lappas A., Kociok N., Kirchhof B., and Joussen A.M. Contribution of TNF-alpha to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo. Invest. Ophthalmol. Vis. Sci. 44 5 (2003) 2184-2191
23. Ledebur H.C., and Parks T.P. Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. Essential roles of a variant NF-kappa B site and p65 homodimers. J. Biol. Chem. 270 2 (1995) 933-943
24. Lopes de Faria J.M., Jalkh A.E., Trempe C.L., and McMeel J.W. Diabetic macular edema: risk factors and concomitants. Acta Ophthalmol. Scand. 77 2 (1999) 170-175
25. Ludwig S., and Shen G.X. Statins for diabetic cardiovascular complications. Curr. Vasc. Pharmacol. 4 3 (2006) 245-251
26. Medina R.J., O'Neill C.L., Devine A.B., Gardiner T.A., and Stitt A.W. The pleiotropic effects of simvastatin on retinal microvascular endothelium has important implications for ischaemic retinopathies. PLoS ONE 3 7 (2008) e2584
27. Mitamura Y., Takeuchi S., Matsuda A., Tagawa Y., Mizue Y., and Nishihira J. Monocyte chemotactic protein-1 in the vitreous of patients with proliferative diabetic retinopathy. Ophthalmologica 215 6 (2001) 415-418
28. Pelzek C., and Lim J.I. Diabetic macular edema: review and update. Ophthalmol. Clin. North Am. 15 (2002) 1-11
29. Qaum T., Xu Q., Joussen A.M., Clemens M.W., Qin W., Miyamoto K., Hassessian H., Wiegand S.J., Rudge J., Yancopoulos G.D., and Adamis A.P. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest. Ophthalmol. Vis. Sci. 42 10 (2001) 2408-2413
30. Romeo G., Liu W.H., Asnaghi V., Kern T.S., and Lorenzi M. Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 51 7 (2002) 2241-2248
31. Sen K., Misra A., Kumar A., and Pandey R.M. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res. Clin. Pract. 56 1 (2002) 1-11
32. Shestakova M.V., Kochemasova T.V., Gorelysheva V.A., Osipova T.V., Polosukhina E.P., Baryshnikov A., and Dedov II. The role of adhesion molecules (ICAM-1 and E-selectin) in development of diabetic microangiopathies. Ter. Arkh. 74 6 (2002) 24-27
33. Tashimo A., Mitamura Y., Nagai S., Nakamura Y., Ohtsuka K., Mizue Y., and Nishihira J. Aqueous levels of macrophage migration inhibitory factor and monocyte chemotactic protein-1 in patients with diabetic retinopathy. Diabet. Med. 21 12 (2004) 1292-1297
34. The Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch. Ophthalmol. 122 4 (2004) 552-563
35. Vinores S.A., Derevjanik N.L., Ozaki H., Okamoto N., and Campochiaro P.A. Cellular mechanisms of blood-retinal barrier dysfunction in macular edema. Doc. Ophthalmol. 97 3-4 (1999) 217-228
36. Wu M., Chen Y., Wilson K., Chirindel A., Ihnat M., Yu Y., Boulton M.E., Szweda L.I., Ma J.X., and Lyons T.J. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. (2008 Mar 24) [Epub ahead of print]
37. Zhang S.X., Wang J.J., Gao G., Shao C., Mott R., and Ma J.-X. Pigment epithelium-derived factor (PEDF) is an endogenous anti-inflammatory factor. FASEB J. 20 2 (2006) 323-325
38. Zhang S.X., Wang J.J., Mott R., Chen Y., Knapp R.R., Cao W., and Ma J.X. Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 294 5 (2008) F1166-1173